mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Application, By Indication, By End-use, By Region, And Segment Forecasts, 2024 - 2030

mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Application, By Indication, By End-use, By Region, And Segment Forecasts, 2024 - 2030

mRNA Therapeutics Contract Development & Manufacturing Organization Market Growth & Trends

The global mRNA therapeutics contract development & manufacturing organization market size is expected to reach USD 8.35 billion by 2030, registering a CAGR of 11.28% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing technological advancements in mRNA and cellular delivery systems, coupled with their cost effectiveness, manufacturing simplicity, and ability to target previously undruggable pathways, have limitless potential to revolutionize medicine. This could represent lucrative growth opportunities for the market. Increasing R&D investments to develop mRNA therapeutics and a strong product pipeline are also propelling the market’s growth. For instance, Moderna shared that R&D expenses for the fourth quarter of 2023 increased by 16% to USD 1.4 billion compared to the same quarter of 2022.

The R&D spending was driven by increased clinical manufacturing activities, with the company’s Cytomegalovirus (CMV) vaccine, RSV vaccine, and combination vaccine against COVID-19 & flu, as well as its individualized neoantigen therapy. Such factors are expected to boost research efforts in mRNA therapeutics. In addition, developing novel therapeutics to address unmet medical needs is altering the product market. The rise in molecular complexity drives the need for in-depth knowledge in research and manufacturing services, as well as the technology to enable sustainable expression and scale-up of novel molecular formats. Platform technologies, such as those for bioconjugation or the creation of bispecific antibodies, can drastically shorten development and production times, and customers are looking for skilled CDMOs who can assist them shorten the time to market and reducing investment risk. Consequently, the need for CDMOs to design and produce goods for the pharmaceutical and biotechnology industries is growing exponentially.

mRNA Therapeutics Contract Development & Manufacturing Organization Market Report Highlights

• The viral vaccines segment dominated the market with a share of 100.00% in 2023. Growth in the segment can be attributed to the rising availability and launch of various vaccines for the treatment of viral infection (COVID-19)
• The infectious diseases segment held the largest market share in 2023 due to the growing incidence of infectious diseases, several advantages of mRNA vaccine over conventional vaccines, emerging clinical studies & pipeline analysis, and increasing collaboration between pharmaceutical companies & CDMO for production
• The biotech companies end-use segment dominated the market and accounted for a share of more than 60.00% in 2023. The segment growth is driven by increasing strategic initiatives, such as partnerships & collaborations with CDMOs, to manufacture mRNA vaccines
• Asia Pacific is expected to register the fastest growth rate of 10.83% from 2024 to 2030. Due to the rising number of pharmaceutical companies and contract manufacturing organizations in developing countries like India and China, Asia Pacific is likely to overtake Europe and North America in the near future

Please note The report will be delivered in 2-3 business days upon order notification.